Cargando…
Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders
BACKGROUND: In gastroenterological disorders, iron deficiency (ID) is often treated with intravenous iron. This real-world study assessed the effectiveness and safety of iron isomaltoside (IIM), a high-dose intravenous iron, for the treatment of ID in patients with gastroenterological disorders, as...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231433/ https://www.ncbi.nlm.nih.gov/pubmed/34249310 http://dx.doi.org/10.1136/flgastro-2020-101406 |
_version_ | 1783713423628959744 |
---|---|
author | Kearns, Jackie Jacob, Sudheer George |
author_facet | Kearns, Jackie Jacob, Sudheer George |
author_sort | Kearns, Jackie |
collection | PubMed |
description | BACKGROUND: In gastroenterological disorders, iron deficiency (ID) is often treated with intravenous iron. This real-world study assessed the effectiveness and safety of iron isomaltoside (IIM), a high-dose intravenous iron, for the treatment of ID in patients with gastroenterological disorders, as part of a service evaluation and improvement process. METHODS: Medical records of 117 patients with gastroenterological disorders, who received IIM, were examined retrospectively. Study outcomes included dose of IIM (estimated iron need versus actual dose received), number of appointments required to deliver the dose and changes in haemoglobin (Hb) and ferritin at ~1 month and ~6 months post-treatment. Safety was assessed through adverse drug reactions (ADRs). RESULTS: Overall, 76.1% of patients received their estimated iron need; 23.9% were underdosed. The mean (SD) iron dose was 1317 (409.7) mg; 62.4% of patients received their dose in one appointment. From baseline, mean (SD) Hb increased by 20.9 (15.4) g/L at 1 month post-treatment (p<0.0001) and by 22.0 (17.9) g/L at 6 months post-treatment (p<0.0001). Mean (SD) baseline ferritin was 26.6 (37.8) μg/L, which increased to 234.6 (142.9) μg/L at 1 month post-treatment (p<0.0001), and remained increased at 6 months post-treatment (122.8 (99.2) μg/L; p<0.0001). A substantial proportion of patients were non-anaemic at 1 month (57.5%) and 6 months (61.8%) post-treatment. At both post-treatment timepoints, the proportion of non-anaemic patients was higher in those receiving their total iron need versus those who were underdosed. No serious ADRs were reported. CONCLUSION: IIM was efficacious and well tolerated in patients with gastroenterological disorders. This real-world study highlights the importance of administering the full iron need to maximise treatment response. |
format | Online Article Text |
id | pubmed-8231433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-82314332021-07-09 Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders Kearns, Jackie Jacob, Sudheer George Frontline Gastroenterol Small Bowel and Nutrition BACKGROUND: In gastroenterological disorders, iron deficiency (ID) is often treated with intravenous iron. This real-world study assessed the effectiveness and safety of iron isomaltoside (IIM), a high-dose intravenous iron, for the treatment of ID in patients with gastroenterological disorders, as part of a service evaluation and improvement process. METHODS: Medical records of 117 patients with gastroenterological disorders, who received IIM, were examined retrospectively. Study outcomes included dose of IIM (estimated iron need versus actual dose received), number of appointments required to deliver the dose and changes in haemoglobin (Hb) and ferritin at ~1 month and ~6 months post-treatment. Safety was assessed through adverse drug reactions (ADRs). RESULTS: Overall, 76.1% of patients received their estimated iron need; 23.9% were underdosed. The mean (SD) iron dose was 1317 (409.7) mg; 62.4% of patients received their dose in one appointment. From baseline, mean (SD) Hb increased by 20.9 (15.4) g/L at 1 month post-treatment (p<0.0001) and by 22.0 (17.9) g/L at 6 months post-treatment (p<0.0001). Mean (SD) baseline ferritin was 26.6 (37.8) μg/L, which increased to 234.6 (142.9) μg/L at 1 month post-treatment (p<0.0001), and remained increased at 6 months post-treatment (122.8 (99.2) μg/L; p<0.0001). A substantial proportion of patients were non-anaemic at 1 month (57.5%) and 6 months (61.8%) post-treatment. At both post-treatment timepoints, the proportion of non-anaemic patients was higher in those receiving their total iron need versus those who were underdosed. No serious ADRs were reported. CONCLUSION: IIM was efficacious and well tolerated in patients with gastroenterological disorders. This real-world study highlights the importance of administering the full iron need to maximise treatment response. BMJ Publishing Group 2020-05-13 /pmc/articles/PMC8231433/ /pubmed/34249310 http://dx.doi.org/10.1136/flgastro-2020-101406 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Small Bowel and Nutrition Kearns, Jackie Jacob, Sudheer George Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders |
title | Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders |
title_full | Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders |
title_fullStr | Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders |
title_full_unstemmed | Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders |
title_short | Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders |
title_sort | real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders |
topic | Small Bowel and Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231433/ https://www.ncbi.nlm.nih.gov/pubmed/34249310 http://dx.doi.org/10.1136/flgastro-2020-101406 |
work_keys_str_mv | AT kearnsjackie realworldevaluationofanintravenousironserviceforthetreatmentofirondeficiencyinpatientswithgastroenterologicaldisorders AT jacobsudheergeorge realworldevaluationofanintravenousironserviceforthetreatmentofirondeficiencyinpatientswithgastroenterologicaldisorders |